These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37957561)

  • 1. Prevalence of chronic kidney disease in the Netherlands and its cardiovascular and renal complications.
    Vervloet MG; de Jong HJ; Pander J; Overbeek JA
    BMC Nephrol; 2023 Nov; 24(1):337. PubMed ID: 37957561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study.
    Folkerts K; Kelly AMB; Petruski-Ivleva N; Fried L; Blankenburg M; Gay A; Velentgas P; Kovesdy CP
    Nephron; 2021; 145(4):342-352. PubMed ID: 33789294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
    Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
    Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
    Filippatos G; Anker SD; Pitt B; Rossing P; Joseph A; Kolkhof P; Lambelet M; Lawatscheck R; Bakris GL; Ruilope LM; Agarwal R
    JACC Heart Fail; 2022 Nov; 10(11):860-870. PubMed ID: 36328655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
    Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
    JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic kidney disease among US adults with type 2 diabetes and cardiovascular diseases: A national estimate of prevalence by KDIGO 2012 classification.
    Wang T; Xi Y; Lubwama R; Hannanchi H; Iglay K; Koro C
    Diabetes Metab Syndr; 2019; 13(1):612-615. PubMed ID: 30641775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The number of nephroprotection targets attained is associated with cardiorenal outcomes and mortality in patients with diabetic kidney disease. The CKD-REIN cohort study.
    Bonnet F; Balkau B; Lambert O; Diawara Y; Combe C; Frimat L; Laville M; Liabeuf S; Massy ZA; Metzger M; Stengel B; Alencar de Pinho N; Fouque D
    Diabetes Obes Metab; 2024 May; 26(5):1908-1918. PubMed ID: 38418407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prevalence and drug treatment of people with type 2 diabetes mellitus and a very high risk of cardiovascular disease].
    Serné EH; Overbeek JA; Palmen J; de Jong HJI; Stehouwer CDA
    Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37742128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes.
    Nichols GA; Déruaz-Luyet A; Brodovicz KG; Kimes TM; Rosales AG; Hauske SJ
    BMC Nephrol; 2020 May; 21(1):167. PubMed ID: 32380961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
    Shubrook JH; Neumiller JJ; Wright E
    Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-Year Risk-Prediction Equations for Incident Heart Failure Hospitalizations in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort Study and the Multi-Ethnic Study of Atherosclerosis.
    Mehta R; Ning H; Bansal N; Cohen J; Srivastava A; Dobre M; Michos ED; Rahman M; Townsend R; Seliger S; Lash JP; Isakova T; Lloyd-Jones DM; Khan SS
    J Card Fail; 2022 Apr; 28(4):540-550. PubMed ID: 34763078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterising the burden of chronic kidney disease among people with type 2 diabetes in England: a cohort study using the Clinical Practice Research Datalink.
    Cook S; Schmedt N; Broughton J; Kalra PA; Tomlinson LA; Quint JK
    BMJ Open; 2023 Mar; 13(3):e065927. PubMed ID: 36882249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
    Agarwal R; Anker SD; Filippatos G; Pitt B; Rossing P; Ruilope LM; Boletis J; Toto R; Umpierrez GE; Wanner C; Wada T; Scott C; Joseph A; Ogbaa I; Roberts L; Scheerer MF; Bakris GL
    Nephrol Dial Transplant; 2022 Jun; 37(7):1261-1269. PubMed ID: 34850173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between urine albumin-to-creatinine ratio and urine protein dipstick testing for prevalence and ability to predict the risk for chronic kidney disease in the general population (Iwate-KENCO study): a prospective community-based cohort study.
    Koeda Y; Tanaka F; Segawa T; Ohta M; Ohsawa M; Tanno K; Makita S; Ishibashi Y; Itai K; Omama SI; Onoda T; Sakata K; Ogasawara K; Okayama A; Nakamura M
    BMC Nephrol; 2016 May; 17(1):46. PubMed ID: 27169575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acteyl-ß-D-glucosaminidase and kidney injury molecule-1: New predictors for long-term progression of chronic kidney disease in patients with heart failure.
    Jungbauer CG; Uecer E; Stadler S; Birner C; Buchner S; Maier LS; Luchner A
    Nephrology (Carlton); 2016 Jun; 21(6):490-8. PubMed ID: 26422793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic kidney disease begets heart failure and vice versa: temporal associations between heart failure events in relation to incident chronic kidney disease in type 2 diabetes.
    Wu MZ; Teng TK; Tay WT; Ren QW; Tromp J; Ouwerkerk W; Chandramouli C; Huang JY; Chan YH; Teramoto K; Yu SY; Lawson C; Li HL; Tse YK; Li XL; Hung D; Tse HF; Lam CSP; Yiu KH
    Diabetes Obes Metab; 2023 Mar; 25(3):707-715. PubMed ID: 36346045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study.
    Birkeland KI; Bodegard J; Eriksson JW; Norhammar A; Haller H; Linssen GCM; Banerjee A; Thuresson M; Okami S; Garal-Pantaler E; Overbeek J; Mamza JB; Zhang R; Yajima T; Komuro I; Kadowaki T
    Diabetes Obes Metab; 2020 Sep; 22(9):1607-1618. PubMed ID: 32363737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
    Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.